{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T02:28:01Z","timestamp":1793672881125,"version":"4.5.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s10072-026-09428-z","type":"journal-article","created":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T06:21:23Z","timestamp":1790230883000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness of atogepant in migraine with and without medication overuse: Pooled real-world analysis of two independent clinical cohorts"],"prefix":"10.1007","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-4913-9232","authenticated-orcid":false,"given":"Marcella","family":"De Luca","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludovica","family":"Ferra\u00f9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Stella","family":"Adragna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Cafarchio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosario","family":"Grugno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Vita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Lo Presti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Cosenza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Autunno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,24]]},"reference":[{"key":"9428_CR1","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1007\/s40122-021-00331-3","volume":"10","author":"P Pozo-Rosich","year":"2021","unstructured":"Pozo-Rosich P, Lucas C, Watson DPB, Gaul C, Ramsden E, Ritter S, Martelletti P, Snellman J (2021) Burden of Migraine in Patients With Preventive Treatment Failure Attending European Headache Specialist Centers: Real-World Evidence From the BECOME Study. Pain Ther 10:1691\u20131708. https:\/\/doi.org\/10.1007\/s40122-021-00331-3","journal-title":"Pain Ther"},{"key":"9428_CR2","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1007\/s40122-023-00538-6","volume":"12","author":"J Pascual","year":"2023","unstructured":"Pascual J, N\u00fa\u00f1ez M, Panni T, D\u00edaz-Cerezo S, Novick D, Ciudad A (2023) Burden and Unmet Needs in Migraine Patients: Results from the OVERCOME (Spain) Study. Pain Ther 12:1209\u20131220. https:\/\/doi.org\/10.1007\/s40122-023-00538-6","journal-title":"Pain Ther"},{"key":"9428_CR3","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s10194-020-01130-5","volume":"21","author":"S Sacco","year":"2020","unstructured":"Sacco S, Braschinsky M, Ducros A, Lampl C, Little P, van den Brink AM, Pozo-Rosich P, Reuter U, de la Torre ER, Sanchez Del Rio M et al (2020) European Headache Federation Consensus on the Definition of Resistant and Refractory Migraine: Developed with the Endorsement of the European Migraine & Headache Alliance (EMHA). J Headache Pain 21:76. https:\/\/doi.org\/10.1186\/s10194-020-01130-5","journal-title":"J Headache Pain"},{"key":"9428_CR4","doi-asserted-by":"publisher","first-page":"333102425136776","DOI":"10.1177\/03331024251367767","volume":"45","author":"J Robblee","year":"2025","unstructured":"Robblee J, Khan FA, Marmura MJ, O\u2019Brien HL, Robbins LD, Samaha MK, Levin M, Sacco S, Ornello R, Nahas SJ et al (2025) Reaching International Consensus on the Definition of Refractory Migraine Using the Delphi Method. Cephalalgia 45:3331024251367767. https:\/\/doi.org\/10.1177\/03331024251367767","journal-title":"Cephalalgia"},{"key":"9428_CR5","doi-asserted-by":"publisher","first-page":"367","DOI":"10.2147\/JPR.S46071","volume":"7","author":"ES Kristoffersen","year":"2014","unstructured":"Kristoffersen ES, Lundqvist C (2014) Medication-Overuse Headache: A Review. J Pain Res 7:367\u2013378. https:\/\/doi.org\/10.2147\/JPR.S46071","journal-title":"J Pain Res"},{"key":"9428_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2023.104943","author":"R Ornello","year":"2024","unstructured":"Ornello R, Andreou AP, Matteis ED, J\u00fcrgens TP, Minen MT, Sacco S (2024) Resistant and refractory migraine: clinical presentation, pathophysiology, and management. EBioMedicine. https:\/\/doi.org\/10.1016\/j.ebiom.2023.104943","journal-title":"EBioMedicine"},{"key":"9428_CR7","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1177\/0333102413485658","volume":"33","author":"Headache Classification Committee of the International Headache Society (IHS)","year":"2013","unstructured":"Headache Classification Committee of the International Headache Society (IHS) (2013) The International Classification of Headache Disorders, 3rd Edition (Beta Version). Cephalalgia 33:629\u2013808. https:\/\/doi.org\/10.1177\/0333102413485658","journal-title":"Cephalalgia"},{"key":"9428_CR8","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1177\/0333102413515344","volume":"34","author":"AL Green","year":"2014","unstructured":"Green AL, Gu P, De Felice M, Dodick D, Ossipov MH, Porreca F (2014) Increased Susceptibility to Cortical Spreading Depression in an Animal Model of Medication-Overuse Headache. Cephalalgia 34:594\u2013604. https:\/\/doi.org\/10.1177\/0333102413515344","journal-title":"Cephalalgia"},{"key":"9428_CR9","doi-asserted-by":"publisher","first-page":"333102425131446","DOI":"10.1177\/03331024251314460","volume":"45","author":"M Romozzi","year":"2025","unstructured":"Romozzi M, Scipioni L, Di Tella S, Silveri MC, Cupini LM, Vollono C, Maccarrone M, Calabresi P (2025) Genetic Characterization of the Endocannabinoid System and Psychiatric Features in Patients with Migraine and Medication Overuse Headache. Cephalalgia 45:3331024251314460. https:\/\/doi.org\/10.1177\/03331024251314460","journal-title":"Cephalalgia"},{"key":"9428_CR10","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1177\/0333102411402367","volume":"31","author":"ID Meng","year":"2011","unstructured":"Meng ID, Dodick D, Ossipov MH, Porreca F (2011) Pathophysiology of Medication Overuse Headache: Insights and Hypotheses from Preclinical Studies. Cephalalgia 31:851\u2013860. https:\/\/doi.org\/10.1177\/0333102411402367","journal-title":"Cephalalgia"},{"key":"9428_CR11","doi-asserted-by":"publisher","unstructured":"Diener H-C, Kropp P, Dresler T, Evers S, F\u00f6rderreuther S, Gaul C, Holle-Lee D, May A, Niederberger U, Moll S et al (2022) Management of Medication Overuse (MO) and Medication Overuse Headache (MOH) S1 Guideline. Neurol Res Pract 4. https:\/\/doi.org\/10.1186\/s42466-022-00200-0","DOI":"10.1186\/s42466-022-00200-0"},{"key":"9428_CR12","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/1129-2377-14-10","volume":"14","author":"P Rossi","year":"2013","unstructured":"Rossi P, Faroni JV, Tassorelli C, Nappi G (2013) Advice Alone versus Structured Detoxification Programmes for Complicated Medication Overuse Headache (MOH): A Prospective, Randomized, Open-Label Trial. J Headache Pain 14:10. https:\/\/doi.org\/10.1186\/1129-2377-14-10","journal-title":"J Headache Pain"},{"key":"9428_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-022-00415-0","author":"S Ashina","year":"2023","unstructured":"Ashina S, Terwindt GM, Steiner TJ, Lee MJ, Porreca F, Tassorelli C, Schwedt TJ, Jensen RH, Diener H-C, Lipton RB (2023) Medication overuse headache. Nat Rev Dis Primers. https:\/\/doi.org\/10.1038\/s41572-022-00415-0","journal-title":"Nat Rev Dis Primers"},{"key":"9428_CR14","doi-asserted-by":"publisher","first-page":"333102425132980","DOI":"10.1177\/03331024251329808","volume":"45","author":"M Silvestro","year":"2025","unstructured":"Silvestro M, Orologio I, Sozio P, Dortucci V, Trojsi F, Siciliano M, Tedeschi G, Tessitore A, Russo A (2025) No Additional Benefit with Detoxification Strategies: A Real World Experience in 200 Patients with Chronic Migraine and Either Simple or Complex MOH Treated with CGRP Monoclonal Antibodies. Cephalalgia 45:3331024251329808. https:\/\/doi.org\/10.1177\/03331024251329808","journal-title":"Cephalalgia"},{"key":"9428_CR15","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1177\/03331024211067791","volume":"42","author":"U Pensato","year":"2022","unstructured":"Pensato U, Baraldi C, Favoni V, Mascarella D, Matteo E, Andrini G, Cainazzo MM, Cortelli P, Pierangeli G, Guerzoni S et al (2022) Detoxification vs Non-Detoxification before Starting an Anti-CGRP Monoclonal Antibody in Medication Overuse Headache. Cephalalgia 42:645\u2013653. https:\/\/doi.org\/10.1177\/03331024211067791","journal-title":"Cephalalgia"},{"key":"9428_CR16","doi-asserted-by":"publisher","unstructured":"Krymchantowski A, Jevoux C, Krymchantowski AG, Ramos LB, Barbosa JSS, Silva-Neto RP (2023) Medication-Overuse Headache\u2014a Review of Different Treatment Strategies. Front Pain Res 4. https:\/\/doi.org\/10.3389\/fpain.2023.1103497","DOI":"10.3389\/fpain.2023.1103497"},{"key":"9428_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/0333102417738202","volume":"38","author":"Headache Classification Committee of the International Headache Society (IHS)","year":"2018","unstructured":"Headache Classification Committee of the International Headache Society (IHS) (2018) The International Classification of Headache Disorders, 3rd Edition. Cephalalgia 38:1\u2013211. https:\/\/doi.org\/10.1177\/0333102417738202","journal-title":"Cephalalgia"},{"key":"9428_CR18","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.pneurobio.2009.07.005","volume":"89","author":"F Galletti","year":"2009","unstructured":"Galletti F, Cupini LM, Corbelli I, Calabresi P, Sarchielli P (2009) Pathophysiological Basis of Migraine Prophylaxis. Prog Neurobiol 89:176\u2013192. https:\/\/doi.org\/10.1016\/j.pneurobio.2009.07.005","journal-title":"Prog Neurobiol"},{"key":"9428_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-024-01755-w","author":"H Gosalia","year":"2024","unstructured":"Gosalia H, Moreno-Ajona D, Goadsby PJ (2024) Medication-overuse headache: a narrative review. J Headache Pain. https:\/\/doi.org\/10.1186\/s10194-024-01755-w","journal-title":"J Headache Pain"},{"key":"9428_CR20","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1001\/jamaneurol.2020.1179","volume":"77","author":"LN Carlsen","year":"2020","unstructured":"Carlsen LN, Munksgaard SB, Nielsen M, Engelstoft IMS, Westergaard ML, Bendtsen L, Jensen RH (2020) Comparison of 3 Treatment Strategies for Medication Overuse Headache: A Randomized Clinical Trial. JAMA Neurol 77:1069\u20131078. https:\/\/doi.org\/10.1001\/jamaneurol.2020.1179","journal-title":"JAMA Neurol"},{"key":"9428_CR21","doi-asserted-by":"publisher","unstructured":"Judith A Pijpers, Dennis A Kies, Mark A Louter, Erik W van Zwet, Michel D Ferrari, Gisela M Terwindt (2019) Acute withdrawal and botulinum toxin A in chronic migraine with medication overuse: a double-blind randomized controlled trial, Brain 142(5):1203\u20131214. https:\/\/doi.org\/10.1093\/brain\/awz052","DOI":"10.1093\/brain\/awz052"},{"key":"9428_CR22","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1111\/ene.15256","volume":"29","author":"JA Pijpers","year":"2022","unstructured":"Pijpers JA, Kies DA, van Zwet EW, Rosendaal FR, Terwindt GM (2022) Behavioural Intervention in Medication Overuse Headache: A Concealed Double-Blind Randomized Controlled Trial. Eur J Neurol 29:1496\u20131504. https:\/\/doi.org\/10.1111\/ene.15256","journal-title":"Eur J Neurol"},{"key":"9428_CR23","doi-asserted-by":"publisher","unstructured":"Tassorelli C, Jensen R, Allena M et al (2017) The added value of an electronic monitoring and alerting system in the management of medication-overuse headache: A controlled multicentre study. Cephalalgia 37(12):1115\u20131125. https:\/\/doi.org\/10.1177\/0333102416660549","DOI":"10.1177\/0333102416660549"},{"key":"9428_CR24","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1111\/head.14036","volume":"61","author":"H-C Diener","year":"2021","unstructured":"Diener H-C, Marmura MJ, Tepper SJ, Cowan R, Starling AJ, Diamond ML, Hirman J, Mehta L, Brevig T, Sperling B et al (2021) Efficacy, Tolerability, and Safety of Eptinezumab in Patients with a Dual Diagnosis of Chronic Migraine and Medication-Overuse Headache: Subgroup Analysis of PROMISE-2. Headache: J Head Face Pain 61:125\u2013136. https:\/\/doi.org\/10.1111\/head.14036","journal-title":"Headache: J Head Face Pain"},{"key":"9428_CR25","doi-asserted-by":"publisher","first-page":"e2309","DOI":"10.1212\/WNL.0000000000007497","volume":"92","author":"SJ Tepper","year":"2019","unstructured":"Tepper SJ, Diener H-C, Ashina M, Brandes JL, Friedman DI, Reuter U, Cheng S, Nilsen J, Leonardi DK, Lenz RA et al (2019) Erenumab in Chronic Migraine with Medication Overuse: Subgroup Analysis of a Randomized Trial. Neurology 92:e2309\u2013e2320. https:\/\/doi.org\/10.1212\/WNL.0000000000007497","journal-title":"Neurology"},{"key":"9428_CR26","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s10194-020-01173-8","volume":"21","author":"SD Silberstein","year":"2020","unstructured":"Silberstein SD, Cohen JM, Seminerio MJ, Yang R, Ashina S, Katsarava Z (2020) The Impact of Fremanezumab on Medication Overuse in Patients with Chronic Migraine: Subgroup Analysis of the HALO CM Study. J Headache Pain 21:114. https:\/\/doi.org\/10.1186\/s10194-020-01173-8","journal-title":"J Headache Pain"},{"key":"9428_CR27","unstructured":"Pearlman DWD, Erin G, Doty,Sheena K, Aurora,Dustin D, Ruff,Virginia L Stauffer,Jakub Jedynak,Yan Dong,Eric M. Medication Overuse in a Subgroup Analysis of Phase 3 Placebo-Controlled Studies of Galcanezumab in the Prevention of Episodic and Chronic Migraine - David W Dodick, Erin G Doty, Sheena K Aurora, Dustin D Ruff, Virginia L Stauffer, Jakub Jedynak, Yan Dong, Eric M, Pearlman (2021) Cephalalgia 2020"},{"key":"9428_CR28","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/S0140-6736(23)01049-8","volume":"402","author":"P Pozo-Rosich","year":"2023","unstructured":"Pozo-Rosich P, Ailani J, Ashina M, Goadsby PJ, Lipton RB, Reuter U, Guo H, Schwefel B, Lu K, Boinpally R et al (2023) Atogepant for the Preventive Treatment of Chronic Migraine (PROGRESS): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial. Lancet 402:775\u2013785. https:\/\/doi.org\/10.1016\/S0140-6736(23)01049-8","journal-title":"Lancet"},{"key":"9428_CR29","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/S1474-4422(24)00025-5","volume":"23","author":"C Tassorelli","year":"2024","unstructured":"Tassorelli C, Nagy K, Pozo-Rosich P, Lanteri-Minet M, Sacco S, Ne\u017e\u00e1dal T, Guo H, De Abreu Ferreira R, Forero G, Trugman JM (2024) Safety and Efficacy of Atogepant for the Preventive Treatment of Episodic Migraine in Adults for Whom Conventional Oral Preventive Treatments Have Failed (ELEVATE): A Randomised, Placebo-Controlled, Phase 3b Trial. Lancet Neurol 23:382\u2013392. https:\/\/doi.org\/10.1016\/S1474-4422(24)00025-5","journal-title":"Lancet Neurol"},{"key":"9428_CR30","doi-asserted-by":"publisher","first-page":"e209584","DOI":"10.1212\/WNL.0000000000209584","volume":"103","author":"PJ Goadsby","year":"2024","unstructured":"Goadsby PJ, Friedman DI, Holle-Lee D, Demarquay G, Ashina S, Sakai F, Neel B, Gandhi P, Dabruzzo B, Smith JH et al (2024) Efficacy of Atogepant in Chronic Migraine With and Without Acute Medication Overuse in the Randomized, Double-Blind, Phase 3 PROGRESS Trial. Neurology 103:e209584. https:\/\/doi.org\/10.1212\/WNL.0000000000209584","journal-title":"Neurology"},{"key":"9428_CR31","doi-asserted-by":"publisher","first-page":"033310242513359","DOI":"10.1177\/03331024251335927","volume":"45","author":"F Vernieri","year":"2025","unstructured":"Vernieri F, Iannone LF, Lo Castro F, Sebastianelli G, De Santis F, Corrado M, Marcosano M, Ornello R, Grazzi L, Montisano DA et al (2025) Effectiveness and Tolerability of Atogepant in the Prevention of Migraine: A Real Life, Prospective, Multicentric Study (the STAR Study). Cephalalgia 45:03331024251335927. https:\/\/doi.org\/10.1177\/03331024251335927","journal-title":"Cephalalgia"},{"key":"9428_CR32","doi-asserted-by":"publisher","unstructured":"Russo A, Silvestro M, Finkelstein I et al (2025) Effectiveness and tolerability of atogepant as preventive treatment in resistant individuals with chronic migraine: Six-month real-world evidence. Cephalalgia 45(8). https:\/\/doi.org\/10.1177\/03331024251370608","DOI":"10.1177\/03331024251370608"},{"key":"9428_CR33","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s10194-025-02068-2","volume":"26","author":"P Barbanti","year":"2025","unstructured":"Barbanti P, Egeo G, Pistoia F, Aurilia C, Scatena P, Rinalduzzi S, Strumia S, Salerno A, Frediani F, Galli A et al (2025) GIANT: A Prospective, Multicenter, Real-World Study on the Effectiveness, Safety, and Tolerability of Atogepant in Migraine Patients with Multiple Therapeutic Failures. J Headache Pain 26:122. https:\/\/doi.org\/10.1186\/s10194-025-02068-2","journal-title":"J Headache Pain"},{"key":"9428_CR34","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s10194-023-01644-8","volume":"24","author":"A Labastida-Ram\u00edrez","year":"2023","unstructured":"Labastida-Ram\u00edrez A, Caronna E, Gollion C, Stanyer E, Dapkute A, Braniste D, Naghshineh H, Meksa L, Chkhitunidze N, Gudadze T et al (2023) Mode and Site of Action of Therapies Targeting CGRP Signaling. J Headache Pain 24:125. https:\/\/doi.org\/10.1186\/s10194-023-01644-8","journal-title":"J Headache Pain"},{"key":"9428_CR35","doi-asserted-by":"publisher","first-page":"2884","DOI":"10.1093\/brain\/awae062","volume":"147","author":"A Melo-Carrillo","year":"2024","unstructured":"Melo-Carrillo A, Strassman AM, Broide R, Adams A, Dabruzzo B, Brin M, Burstein R (2024) Novel Insight into Atogepant Mechanisms of Action in Migraine Prevention. Brain 147:2884\u20132896. https:\/\/doi.org\/10.1093\/brain\/awae062","journal-title":"Brain"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-026-09428-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-026-09428-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-026-09428-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T02:03:05Z","timestamp":1793671385000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-026-09428-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,24]]},"references-count":35,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["9428"],"URL":"https:\/\/doi.org\/10.1007\/s10072-026-09428-z","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,24]]},"assertion":[{"value":"29 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflicts of interest relevant to this work.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"805"}}